Profound Medical Corp. 04.05.17
Profound Medical Corp., an emerging medical device company focused on prostate care, announced that Steven Plymale has resigned his position as president and chief operating officer to pursue other opportunities.
"It has truly been an honor and privilege to have worked alongside the talented team at Profound for the past six years," commented Plymale. "While the decision to leave the company was a difficult one for me, I believe that it is very well-positioned to continue its strong growth trajectory in 2017 and beyond.”
“Steve’s contributions to the development of both the company and our TULSA-PRO system have been immeasurable,” saidd Profound CEO Arun Menawat. “On a personal note, he has been a friend and colleague for many years, and I sincerely wish him the highest level of success in the future.”
Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The Canadian company is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology. If successful, TACT is expected to support Profound's application to the FDA for approval to market TULSA-PRO in the United States.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. The company's mission is to profoundly change the standard of care where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; where patients have access to a safe, fast and effective treatment option..
Established in 2008, Profound Medical is commercializing TULSA-PRO, which combines real-time magnetic resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.
"It has truly been an honor and privilege to have worked alongside the talented team at Profound for the past six years," commented Plymale. "While the decision to leave the company was a difficult one for me, I believe that it is very well-positioned to continue its strong growth trajectory in 2017 and beyond.”
“Steve’s contributions to the development of both the company and our TULSA-PRO system have been immeasurable,” saidd Profound CEO Arun Menawat. “On a personal note, he has been a friend and colleague for many years, and I sincerely wish him the highest level of success in the future.”
Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The Canadian company is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology. If successful, TACT is expected to support Profound's application to the FDA for approval to market TULSA-PRO in the United States.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. The company's mission is to profoundly change the standard of care where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; where patients have access to a safe, fast and effective treatment option..
Established in 2008, Profound Medical is commercializing TULSA-PRO, which combines real-time magnetic resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.
